Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning
Cabrera‐Mendoza B, Martínez‐Magaña J, Monroy‐Jaramillo N, Genis‐Mendoza A, Fresno C, Fries GR, Walss‐Bass C, Armenta M, García‐Dolores F, Díaz‐Otañez C, Flores G, Vázquez‐Roque R, Nicolini H. Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2021, 186: 193-206. PMID: 33403748, DOI: 10.1002/ajmg.b.32830.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersBrain gene co-expression networksHub genesPotential pharmacological targetPost-mortem samplesPharmacological treatmentHigh riskCandidate treatmentPharmacological targetsSuicidal behaviorMAOA inhibitorsPrefrontal cortexNonsuicidesDGIdb databaseGene expression profilesPatientsCo-expression networkSuicideDisordersDrugsTreatmentDrug repositioningExpression profilesIndividualsHigh polygenic burden is associated with blood DNA methylation changes in individuals with suicidal behavior
Cabrera-Mendoza B, Martínez-Magaña JJ, Genis-Mendoza AD, Sarmiento E, Ruíz-Ramos D, Tovilla-Zárate CA, González-Castro TB, Juárez-Rojop IE, García-de la Cruz DD, López-Armenta M, Real F, García-Dolores F, Flores G, Vázquez-Roque RA, Lanzagorta N, Escamilla M, Saucedo-Uribe E, Rodríguez-Mayoral O, Jiménez-Genchi J, Castañeda-González C, Roche-Bergua A, Nicolini H. High polygenic burden is associated with blood DNA methylation changes in individuals with suicidal behavior. Journal Of Psychiatric Research 2020, 123: 62-71. PMID: 32036075, DOI: 10.1016/j.jpsychires.2020.01.008.Peer-Reviewed Original ResearchConceptsDNA methylation differencesMethylation differencesDiscovery samplePolygenic risk scoresDNA methylation changesSuicidal behaviorGenetic burdenPolygenic burdenPsychiatric Genomics ConsortiumEpigenetic variationATP bindingDNA methylationEnvironmental factorsMethylation changesEpigenetic changesGenomics ConsortiumPolygenic componentGenesGenetic variantsPRS analysesRisk scoreMexican individualsBurdenIntegration of approachesNeurodevelopmentBrain Gene Expression Profiling of Individuals With Dual Diagnosis Who Died by Suicide
Cabrera-Mendoza B, Fresno C, Monroy-Jaramillo N, Fries GR, Walss-Bass C, Glahn DC, Ostrosky-Wegman P, Genis-Mendoza AD, Martínez-Magaña JJ, Romero-Pimentel AL, Díaz-Otañez CE, García-Dolores F, González-Sáenz EE, Mendoza-Morales RC, Flores G, Vázquez-Roque R, Nicolini H. Brain Gene Expression Profiling of Individuals With Dual Diagnosis Who Died by Suicide. Journal Of Dual Diagnosis 2019, 16: 177-190. PMID: 31774731, DOI: 10.1080/15504263.2019.1692160.Peer-Reviewed Original ResearchConceptsSubstance use disordersMood disordersDual diagnosisUse disordersMental comorbiditiesGene expression profilesMental disordersSingle disorderCell type enrichmentAdverse clinical outcomesGlial-specific markersMore mental disordersExpression profilesDorsolateral prefrontal cortexClinical outcomesGABAergic neurotransmissionGlial markersHigh riskDisorder patientsComorbiditiesSuicidal behaviorPrefrontal cortexGene expression profilingSynaptic genesDisorders